Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 552.09 Million
CAGR (2026-2031)	10.25%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America
Market Size (2031)	USD 991.47 Million

Market Overview

The Global Bioresorbable Coronary Stents Market will grow from USD 552.09 Million in 2025 to USD 991.47 Million by 2031 at a 10.25% CAGR. Bioresorbable coronary stents are transient scaffolds designed to open blocked arteries and restore blood flow before gradually dissolving, thereby leaving the vessel free of permanent metallic implants. The market is primarily supported by the increasing global prevalence of coronary artery disease and a shifting clinical preference toward minimally invasive interventions that facilitate natural vessel function restoration. Additionally, the potential to reduce long-term thrombotic risks associated with permanent metal stents encourages adoption among interventional cardiologists seeking to improve patient outcomes.

However, a significant challenge impeding rapid market expansion is the requirement for rigorous long-term clinical data to ensure safety profiles comparable to standard drug-eluting stents, which creates a high barrier to regulatory approval. This scrutiny forces manufacturers to invest heavily in extended trials, delaying commercialization. According to the European Society of Cardiology, in 2024, high-income member countries reported a percutaneous coronary intervention rate of 2,330 per million people, underscoring the substantial procedural volume that necessitates continuous innovation in stent technologies despite these regulatory hurdles.

Key Market Drivers

The Rising Global Prevalence of Cardiovascular Diseases acts as the primary engine for the Global Bioresorbable Coronary Stents Market, necessitating advanced therapeutic solutions for an expanding patient population. As coronary artery disease remains a critical global health burden, the demand for interventions that can restore vessel physiology without permanent implantation is intensifying. According to the American Heart Association, January 2025, in the '2025 Heart Disease and Stroke Statistics Update', cardiovascular disease accounted for approximately 19.41 million global deaths in 2021. This substantial mortality burden is further compounded by lifestyle-related risk factors that accelerate disease progression; for instance, according to the World Heart Federation, May 2025, in the 'World Heart Report 2025', annual global cardiovascular deaths attributable to high body mass index reached 1.9 million. These statistics underscore the urgent clinical need for evolving coronary technologies that address complex vascular conditions.

Technological Advancements in Bioresorbable Material Science are propelling the market by overcoming the safety limitations of earlier scaffold generations. Manufacturers are aggressively developing next-generation devices with thinner struts and improved mechanical properties that offer temporary structural support before uncaging the vessel to resume natural function. This progress is validated by recent clinical successes demonstrating superior outcomes over permanent implants. According to Elixir Medical, May 2025, in the 'BIOADAPTOR Randomized Controlled Trial' results presented at EuroPCR, the DynamX coronary bioadaptor demonstrated a statistically significant reduction in target lesion failure rates to 2.7% at three years compared to 7.2% for standard drug-eluting stents. Such positive clinical data is pivotal in re-establishing physician confidence and fostering the adoption of resorbable and adaptive coronary technologies.

Download Free Sample Report

Key Market Challenges

The stringent requirement for rigorous long-term clinical data creates a substantial barrier to the growth of the Global Bioresorbable Coronary Stents Market. Regulatory authorities enforce high evidentiary standards to ensure that these transient scaffolds maintain safety profiles comparable to established drug-eluting stents, particularly regarding risks such as thrombosis during the dissolution phase. This necessity compels manufacturers to invest in multi-year clinical trials before gaining approval, significantly inflating research costs and delaying the commercial timeline. Consequently, this prolonged development cycle creates uncertainty and deters rapid investment, preventing these innovative devices from quickly reaching the market and challenging the dominance of permanent metallic implants.

This regulatory bottleneck directly limits the market's ability to capitalize on the high demand for coronary interventions. Although the burden of heart disease is immense, the slow pace of product validation restricts the availability of bioresorbable options for interventional cardiologists. According to the European Society of Cardiology, in 2024, cardiovascular disease caused more than 3 million deaths annually across its member countries, highlighting the massive patient population requiring effective treatment. However, because manufacturers are impeded by the time-intensive process of generating required safety data, the market remains underpenetrated, and the potential revenue growth from this high procedural volume is effectively stalled.

Key Market Trends

The Transition from Polymer-Based to Magnesium-Based Metallic Scaffolds represents a critical evolution designed to overcome the mechanical inferiority and prolonged resorption times of early poly-L-lactic acid devices. Unlike polymers, magnesium alloys provide superior radial strength and allow for thinner struts, which significantly improves deliverability while reducing the inflammatory burden on the vessel wall. This material shift addresses safety concerns by ensuring the scaffold disappears once the vessel heals, preventing late-stage thrombosis. According to Biotronik, February 2024, in the 'CE-approval for BIOTRONIK's Next-Gen Metallic Bioresorbable Scaffold Freesolve' press release, the BIOMAG-I trial demonstrated an exceptional 99.3% magnesium strut degradation 12 months after implantation, confirming the viability of these metallic platforms to rapidly restore natural vasomotion.

The Implementation of Advanced Imaging for Precision Scaffold Placement is emerging as a mandatory procedural standard to optimize the implantation of bioresorbable devices, which are far less forgiving of sizing errors than permanent metallic stents. Interventional cardiologists are increasingly utilizing optical coherence tomography to ensure proper scaffold expansion and apposition, thereby minimizing the risk of mechanical failure or acute vessel recoil. This integration of imaging guidance is statistically proven to enhance clinical safety in complex interventions, a benefit that is indispensable for the successful deployment of transient scaffolds. According to the European Society of Cardiology, September 2024, in the 'Optical coherence tomography outperforms conventional angiography for stent guidance in complex cases' press release, patients treated with optical coherence tomography guidance experienced a 38% reduction in the combined risk of cardiac death, stent thrombosis, and revascularization compared to standard angiography.

Segmental Insights

The Hospitals and Clinics segment is recognized as the fastest-growing category within the Global Bioresorbable Coronary Stents Market. This expansion is primarily driven by the increasing volume of interventional procedures that demand the specific infrastructure of hospital catheterization laboratories. Additionally, adherence to clinical safety guidelines from authorities such as the European regulatory bodies necessitates that these implantations occur in fully equipped settings to mitigate procedural risks. The capability of hospitals to provide immediate post-operative care and advanced imaging support further accelerates the adoption of bioresorbable technologies in these facilities.

Regional Insights

North America maintains a leading position in the global bioresorbable coronary stents market, driven by the rising prevalence of coronary artery diseases and substantial healthcare expenditure. The region benefits from a robust medical infrastructure that supports the rapid adoption of advanced interventional devices and the strong presence of key manufacturers focused on product development. Additionally, clear clinical frameworks established by regulatory authorities, such as the U.S. Food and Drug Administration, facilitate the rigorous evaluation and approval of emerging stent technologies, thereby reinforcing the region's market dominance.

Recent Developments

• In October 2024, Elixir Medical presented late-breaking twelve-month data from the INFINITY-SWEDEHEART randomized controlled trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The study compared the performance of the DynamX Coronary Bioadaptor System against a contemporary drug-eluting stent in patients with complex lesion subsets. The results, which were simultaneously published in a major medical journal, demonstrated that the bioadaptor's unique mechanism of uncaging the vessel after the resorption of its polymer coating led to statistically significant reductions in target lesion failure and restored vessel pulsatility.
• In July 2024, Shanghai MicroPort Medical (Group) Co., Ltd., a subsidiary of MicroPort Scientific Corporation, obtained marketing approval from China's National Medical Products Administration (NMPA) for the Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System. The company described the device as a second-generation bioresorbable scaffold featuring thin struts comparable to permanent metallic stents. The approval was based on clinical data demonstrating the scaffold's efficacy in treating coronary artery disease and its ability to fully degrade, thereby reducing the risk of long-term foreign body reactions.
• In April 2024, REVA Medical released the final five-year clinical outcomes from the FANTOM II trial, which evaluated the safety and effectiveness of the Fantom bioresorbable coronary artery scaffold. The study assessed the long-term performance of the device, which is constructed from the company’s proprietary Tyrocore polymer. The results provided critical data regarding the scaffold's degradation profile and its ability to maintain vessel patency over an extended period, contributing significant clinical evidence to the field of polymer-based bioresorbable technologies for coronary interventions.
• In February 2024, Biotronik announced the CE mark certification and subsequent commercial launch of the Freesolve resorbable magnesium scaffold (RMS) for the treatment of coronary artery lesions. This third-generation device was engineered to provide optimized vessel support while achieving 99.3% magnesium strut resorption within twelve months of implantation. The company highlighted that the scaffold's design incorporates the proprietary BIOmag magnesium alloy and a drug-eluting coating, aiming to deliver the performance and deliverability of a metallic stent with the long-term benefits of a resorbable scaffold.

Key Market Players

• BIOTRONIK SE & Co. KG
• Meril Life Sciences Pvt. Ltd
• Elixir Medical Corporation.
• Reva Medical, LLC
• Terumo Corporation
• Lepu Medical Technology (Beijing)Co.,Ltd
• MicroPort Scientific Corporation
• LifeTech Scientific Corporation
• Boston Scientific Corporation
• Medtronic plc

By Brand	By End User	By Region
Magmaris Magnitude MeRes-100 DESolve Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bioresorbable Coronary Stents Market, By Brand:

• Magmaris
• Magnitude
• MeRes-100
• DESolve
• Others

• Bioresorbable Coronary Stents Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Bioresorbable Coronary Stents Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE